ASCO Ovarian Cancer Spotlight

Approximately 25% of patients with <em>BRCA</em> wild-type serous ovarian cancer may benefit from treatment with PARP inhibitors, along with 12.7% of patients with a non-serous histology, according to findings of genomic analyses in patients with ovarian cancer presented during the 2017 ASCO Annual Meeting that&nbsp;demonstrate that comprehensive genomic profiling is a valuable tool to integrate into routine ovarian cancer treatment decision making and clinical trial design.

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring&nbsp;mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.

Progression-free survival (PFS) continues to be superior with the combination of cediranib maleate and olaparib (Lynparza) compared with olaparib alone in patients with recurrent platinum-sensitive ovarian cancer in a randomized open-label study with follow-up to December 2016.

Napabucasin, a first-in-class cancer stemness inhibitor, can be safely combined with full-dose weekly paclitaxel to treat patients with advanced, platinum-resistant ovarian cancer.

Patients with recurrent, platinum-sensitive ovarian cancer and germline <em>BRCA</em> mutations had significant improvement in progression-free survival (PFS) with no decrement in health-related quality of life (hr-QoL) during maintenance therapy with olaparib (Lynparza), according to a review of patient-reported outcomes in a randomized trial.

Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, showed promising activity in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.

The PARP inhibitor olaparib (Lynparza) provides clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer, according to the protocol-specified final overall survival (OS) analysis of the phase II Study 19 trial presented during the 2017 ASCO Annual Meeting.

Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with <em>BRCA</em>-mutated platinum-sensitive relapsed serous ovarian cancer.

A second cytoreductive surgery followed by platinum-based chemotherapy extended progression-free survival (PFS) compared with platinum-based chemotherapy alone in patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gyn&auml;kologische Onkologie (AGO) score.